References
-
1
Vader J P, Burnand B, Froehlich F, et al.
The European Panel on Appropriateness of Gastrointestinal Endoscopy (EPAGE): Project and Methods.
Endoscopy.
1999;
31
572-578
-
2
Vader J P, Froehlich F, Dubois R W, et al.
The European Panel on Appropriateness of Gastrointestinal Ensocopy (EPAGE): Conclusions and WWW site.
Endoscopy.
1999;
31
687-694
-
3
Morrissey J F, Reichelderfer M.
Gastrointestinal endoscopy (2).
N Engl J Med.
1991;
325
1214-1222
-
4
Colin-Jones D G.
Management of dyspepsia: report of a working party.
Lancet.
1988;
1
576-579
-
5
Talley N J, Phillips S F.
Non-ulcer dyspepsia: potential causes and pathophysiology.
Ann Intern Med.
1988;
108
865-879
-
6
Barbara L, Camilleri M, Corinaldesi R, et al.
Definition and investigation of dyspepsia. Consensus of an international ad hoc working party.
Dig Dis Sci.
1989;
34
1272-1276
-
7
Malfertheiner P, McColl K, Baldi F, et al.
Update on Helicobacter pylori research. Dyspepsia.
Eur J Gastroenterol Hepatol.
1997;
9
624-625
-
8
Agreus L, Engstrand L, Svardsudd K, et al.
Helicobacter pylori seropositivity among Swedish adults with and without abdominal symptoms. A population-based epidemiologic study.
Scan J Gastroenterol.
1995;
30
752-757
-
9
Veldhuyzen van Zanten S J, Tytgat K M, Pollak P T, et al.
Can severity of symptoms be used as an outcome measure in trials of non-ulcer dyspepsia and Helicobacter pylori associated gastritis?.
J Clin Epidemiol.
1993;
46
273-279
-
10
Bochud M, Gonvers J J, Vader J P, et al.
Appropriateness of gastroscopy: Gastroesophageal reflux disease.
Endoscopy.
1999;
31
596-603
-
11
Talley N J, Weaver A L, Zinsmeister A R, et al.
Onset and disappearance of gastrointestinal symptoms and functional gastrointestinal disorders.
Am J Epidemiol.
1992;
136
165-177
-
12
Talley N J, Zinsmeister A R, Schleck C D, et al.
Dyspepsia and dyspepsia subgroups: a population-based study.
Gastroenterology.
1992;
102
1259-1268
-
13
Jones R H, Lydeard S E, Hobbs F D, et al.
Dyspepsia in England and Scotland.
Gut.
1990;
3
401-405
-
14
Knill-Jones R P.
Geographical differences in the prevalence of dyspepsia.
Scan J Gastroenterol.
1991;
26
17-24
-
15
Jones R.
Dyspeptic symptoms in the community.
Gut.
1989;
30
893-898
-
16
Johnsen R, Bernersen B, Straume B, et al.
Prevalences of endoscopic and histological findings in subjects with and without dyspepsia.
BMJ.
1991;
302
749-752
-
17
Vaira D, Stanghellini V, Menegatti M, et al.
Prospective screening of dyspeptic patients by Helicobacter pylori serology: a safe policy? The Italian Helicobacter pylori Study Group.
Endoscopy.
1997;
29
595-601
-
18
Patel P, Mendall M A, Khulusi S, et al.
Salivary antibodies to Helicobacter pylori: screening dyspeptic patients before endoscopy.
Lancet.
1994;
344
511-512
-
19
Sobala G M, Crabtree J E, Pentith J A, et al.
Screening dyspepsia by serology to Helicobacter pylori.
Lancet.
1991;
338
94-96
-
20
Heikkinen M, Pikkarainen P, Takala J, et al.
Etiology of dyspepsia: four hundred unselected consecutive patients in general practice.
Scan J Gastroenterol.
1995;
30
519-523
-
21
Mansi C, Mela G S, Savarino V, et al.
Open access endoscopy: a large-scale analysis of its use in dyspeptic patients.
J Clin Gastroenterol.
1993;
16
149-153
-
22
Bernersen B, Johnsen R, Bostad L, et al.
Is Helicobacter pylori the cause of dyspepsia?.
BMJ.
1992;
304
1276-1279
-
23
Talley N J, Weaver A L, Tesmer D L, et al.
Lack of discriminant value of dyspepsia subgroups in patients referred for upper endoscopy.
Gastroenterology.
1993;
105
1378-1386
-
24
Hansen J M, Bytzer P, Bondesen S, et al.
Efficacy and outcome of an open access endoscopy service.
Dan Med Bull .
1991;
38
288-290
-
25
Fraser A G, Ali M R, McCullough S, et al.
Diagnostic tests for Helicobacter pylori - can they help select patients for endoscopy?.
New Zealand Medical Journal.
1996;
109
95-98
-
26
Carpenter H A, Talley N J.
Gastroscopy is incomplete without biopsy: clinical relevance of distinguishing gastropathy from gastritis.
Gastroenterology.
1995;
108
917-924
-
27
Richter J E.
Dyspepsia: organic causes and differential characteristics from functional dyspepsia. (Review).
Scand J Gastroenterol Suppl.
1991;
182
11-16
-
28
Williams B, Luckas M, Ellingham J H, et al.
Do young patients with dyspepsia need investigation?.
Lancet.
1988;
2
1349-1351
-
29
Bytzer P, Schaffalitzky de Muckadell O B.
Prediction of major pathologic conditions in dyspeptic patients referred for endoscopy. A prospective validation study of a scoring system.
Scan J Gastroenterol.
1992;
27
987-992
-
30
Kalra L, Price W R, Jones B J, Hamlyn A N.
Open access fibresigmoidoscopy: a comparative audit of efficacy.
Br Med J Clin Res Ed.
1994; 1998;
6629
1095-1096
-
31
Mansi C, Mela G S, Pasini D, et al.
Patterns of dyspepsia in patients with no clinical evidence of organic diseases.
Dig Dis Sci.
1990;
35
1452-1458
-
32
Bytzer P, Hansen J M, Havelund T, et al.
Predicting endoscopic diagnosis in the dyspeptic patient: the value of clinical judgement.
Eur J Gastroenterol Hepatol.
1996;
8
359-363
-
33
Adang R P, Ambergen A W, Talmon J L, et al.
The discriminative value of patient characteristics and dyspeptic symptoms for upper gastrointestinal endoscopic findings: A study on the clinical presentation of 1147 patients.
Digestion.
1996;
57
118-134
-
34
Heading R C, Wager E, Tooley P J.
Reliability of symptom assessment in dyspepsia.
Eur J Gastroenterol Hepatol.
1997;
9
779-781
-
35
Davenport P M, Morgan A G, Darnborough A, de Dombal F T.
Can preliminary screening of dyspeptic patients allow more effective use of investigational techniques?.
Brit Med J Clin Res Ed.
1994; 1985;
6463
217-220
-
36
Numans M E, Van der Graaf Y, de Wit N J, et al.
How much ulcer is ulcer-like? Diagnostic determinants of peptic ulcer in open access gastroscopy.
Family Practice.
1994;
11
382-388
-
37
Muris J W, Starmans R, Pop P.
Discriminant value of symptoms in patients with dyspepsia.
J Fam Pract.
1994;
38
139-143
-
38
Dooley C P, Cohen H, Fitzgibbons P L, et al.
Prevalence of Helicobacter pylori infection and histologic gastritis in asymptomatic persons.
N Engl J Med.
1989;
321
1562-1566
-
39
Graham D Y, Malaty H M, Evans D G, et al.
Epidemiology of Helicobacter pylori in an asymptomatic population in the United States. Effect of age, race, and socioeconomic status.
Gastroenterology.
1991;
100
1495-1501
-
40
Gasbarrini G, Pretolani S, Bonvicini F, et al.
A population based study of Helicobacter pylori infection in a European country: the San Marino study. Relations with gastrointestinal diseases.
Gut.
1995;
36
838-844
-
41
Anonymous.
An international association between helicobacter pylori infection and gastric cancer. The Eurogast study group.
Lancet.
1993;
341
1359-1362
-
42
Goodman K J, Correa P.
The transmission of Helicobacter pylori. A critial review of the evidence.
Int J Epidemiol.
1995;
24
875-887
-
43
Kuipers E J, Pena A S, Van Kamp G, et al.
Seroconversion for Helicobacter pylori infection.
Lancet.
1993;
342
328-331
-
44
Megraud F.
Epidemiology of Helicobacter pylori infection: where are we in 1995?.
Eur J Gastroenterol Hepatol.
1995;
7
292-295
-
45
Graham D Y, Lew G M, Klein P D, et al.
Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study.
Ann Intern Med.
1992;
116
705-708
-
46
Peterson W L.
Helicobacter pylori and peptic ulcer disease (see comments). (Review) (97 refs).
N Engl J Med.
1991;
324
1043-1048
-
47
Rauws E A.
Role of Helicobacter pylori in duodenal ulcer.
Drugs.
1992;
44
921-927
-
48
Hentschel E, Brandstatter G, Dragosics B, et al.
Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer.
N Engl J Med.
1993;
328
308-312
-
49
Veldhuyzen van Zanten S J, Sherman P M.
Helicobacter pylori infection as a cause of gastritis, duodenal ulcer, gastric cancer and nonulcer dyspepsia: a systematic overview.
Can Med Assoc J.
1994;
150
177-185
-
50
Elta G H, Scheiman J M, Barnett J L, et al.
Long-term follow-up of Helicobacter pylori treatment in non-ulcer dyspepsia patients.
Am J Gastroenterol.
1995;
90
1089-1093
-
51
Greenberg R E, Bank S.
The prevalence of Helicobacter pylori in nonulcer dyspepsia. Importance of stratification according to age.
Arch Intern Med.
1990;
150
2053-2055
-
52
Holtmann G, Goebell H, Holtmann M, Talley N J.
Dyspepsia in healthy blood donors. Pattern of symptoms and association with Helicobacter pylori.
Dig Dis Sci.
1994;
39
1090-1098
-
53
Bouche O.
Should Helicobacter pylori be eradicated in a patient with chronic gastritis? (Review) (127 refs) (French).
Gastroenterol Clin Biol.
1996;
20
S143-153
-
54
Armstrong D.
Helicobacter pylori infection and dyspepsia.
Scand J Gastroenterol Suppl.
1996;
215
38-47
-
55
McCarthy C, Patchett S, Collins R M, et al.
Long-term prospective study of Helicobacter pylori in nonulcer dyspepsia.
Dig Dis Sci.
1995;
40
114-119
-
56
Gilvarry J, Buckley M J, Beattie S, et al.
Eradication of Helicobacter pylori affects symptoms in non-ulcer dyspepsia.
Scan J Gastroenterol.
1997;
32
535-540
-
57
Sheu B S, Lin C Y, Lin X Z, et al.
Long-term outcome of triple therapy in Helicobacter pylori-related nonulcer dyspepsia: a prospective controlled assessment.
Am J Gastroenterol.
1996;
91
441-447
-
58
Lazzaroni M, Bargiggia S, Sangaletti O, et al.
Eradication of Helicobacter pylori and long-term outcome of functional dyspepsia. A clinical endoscopic study.
Dig Dis Sci.
1996;
41
1589-1594
-
59
O'Morain C, Gilvarry J.
Eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. (Review) (40 rfs).
Scand J Gastroenterol Suppl.
1993;
196
30-33
-
60
Veldhuyzen van Zanten S J, Malatjalian D.
The effect of eradication of Helicobacter pylori on symptoms of non-ulcer dyspepsia (NUD): a randomized, double blind, placebo-controlled trial (abstract).
Gastroenterology.
1995;
108
A250
-
61
Greenberg P D.
Prospective, double-blind treatment of Helicobacter pylori in patients with non-ulcer dyspepsia. (Abstract).
Gastroenterology.
1996;
110
A123
-
62
Schubert T T, Schubert A B, Ma C K.
Symptoms, gastritis, and Helicobacter pylori in patients referred for endoscopy.
Gastrointest Endosc.
1992;
38
357-360
-
63
McColl K EL.
U.K. MRC trial of H. pylori eradication therapy for non-ulcer dyspepsia. (Abstract).
Gastroenterology.
1998;
114
A222-222
-
64
Koelz H R.
Treatment of Helicobacter pylori does not improve symptoms of functional dyspepsia. (Abstract).
Gastroenterology.
1998;
114
A182-182
-
65
Bretagne J F.
The course of symptoms after eradication of Helicobacter pylori: a one-year follow-up of a cohort of 258 patients with duodenal ulcer or nonulcer dyspepsia. (Abstract).
Gastroenterology.
1998;
114
A81-81
-
66
Talley N J.
Long-term follow-up of patients with non-ulcer dyspepsia after Helicobacter pylori eradication. A randomized double-blind placebo-controlled trial. (Abstract).
Gastroenterology.
1998;
114
A305-305
-
67
Anonymous.
Nih consensus conference. Helicobacter pylori in peptic ulcer disease. Nih consensus development panel on Helicobacter pylori in peptic ulcer disease.
J Am Med Ass.
1994;
272
65-69
-
68 Dyspepsia Management Guidelines. Brit Society of Gastroenterology. http://www.bsg.org.uk/clinical/data/dmg.htm; 1996
-
69
Wilcox C M, Schwartz D A.
Endoscopic characterization of idiopathic esophageal ulceration associated with human immunodeficiency virus infection.
J Clin Gastroenterol.
1993;
16
251-256
-
70
Megraud F.
Advantages and disadvantages of current diagnostic tests for the detection of Helicobacter pylori.
Scand J Gastroenterol Suppl.
1996;
215
57-62
-
71
Ateshkadi A, Lam N P, Johnson C A.
Helicobacter pylori and peptic ulcer disease.
Clin Pharmacy.
1993;
12
34-48
-
72
Laine L, Chun D, Stein C, et al.
The influence of size or number of biopsies on rapid urease test results: a prospective evaluation.
Gastrointest Endosc.
1996;
43
49-53
-
73
Loy C T, Irwig L M, Katelaris P H, Talley N J.
Do commercial serological kits for Helicobacter pylori infection differ in accuracy? A meta-analysis.
Am J Gastroenterol.
1996;
91
1138-1144
-
74
Megraud F.
The most important diagnostic modalities for Helicobacter pylori, now and in the future. (Review) (4 refs).
Eur J Gastroenterol Hepatol.
1997;
1
S13-15
-
75
Malfertheiner P, Megraud F, O'Morain C, et al.
Current european concepts in the management of Helicobacter pylori infection - the Maastricht consensus report. The European Helicobacter pylori study group.
Eur J Gastroenterol Hepatol.
1997;
9
1-2
-
76
Soll A H.
Consensus conference. Medical treatment of peptic ulcer disease. Practice guidelines. Practice parameters committee of the American College of Gastroenterology.
J Am Med Ass.
1996;
275
622-629
-
77
Holtmann G, Layer P, Goebell H.
Proton-pump inhibitors or h2-receptor antagonists for Helicobacter pylori eradication - a meta-analysis (letter).
Lancet.
1996;
347
763
-
78
Labenz J, Gyenes E, Ruhl G H, Borsch G.
Omeprazole plus amoxicillin: efficacy of various treatment regimens to eradicate Helicobacter pylori.
Am J Gastroenterol.
1993;
88
491-495
-
79
Fennerty M B, Lieberman D, Magaret N, et al.
Effectiveness of H. pylori treatment regimens in clinical practice: a community-based outcomes study. (Abstract).
Gastroenterology.
1997;
112
A14-14
-
80
Lee J, O'Morain C.
Consensus or confusion: a review of existing national guidelines on Helicobacter pylori-related disease.
Eur J Gastroenterol Hepatol.
1997;
9
527-531
-
81
Rokkas T, Karameris A, Mavrogeorgis A, et al.
Eradication of Helicobacter pylori reduces the possibility of rebleeding in peptic ulcer disease.
Gastrointest Endosc.
1995;
41
1-4
-
82
Graham D Y, Hepps K S, Ramirez F C, et al.
Treatment of Helicobacter pylori reduces the rate of rebleeding in peptic ulcer disease.
Scan J Gastroenterol.
1993;
28
939-942
-
83
Jaspersen D, Koerner T, Schorr W, et al.
Helicobacter pylori eradication reduces the rate of rebleeding in ulcer hemorrhage.
Gastrointest Endosc.
1995;
41
5-7
-
84
Bayerdorffer E, Neubauer A, Rudolph B, et al.
Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. MALT Lymphoma Study Group.
Lancet.
1995;
345
1591-1594
-
85
Wotherspoon A C, Doglioni C, Diss T C, et al.
Regression of primary low-grade-B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori.
Lancet.
1993;
342
575-577
-
86
Sackmann M, Morgner A, Rudolph B, et al.
Regression of gastric MALT lymphoma after eradication of Helicobacter pylori is predicted by endosonographic staging.
Gastroenterology.
1997;
113
1087-1090
-
87
Veldhuyzen von Z S, Sherman P M, Hunt R H.
Helicobacter pylori: new developments and treatments.
CMAJ.
1997;
156
1565-1574
-
88
Lerang F, Moum B, Ragnhildstveit E, et al.
A comparison between omeprazole-based triple therapy and bismuth-based triple therapy for the treatment of Helicobacter pylori infection: a prospective randomized 1-yr follow-up study.
Am J Gastroenterol.
1997;
92
653-658
-
89
Hopkins R J, Girardi L S, Turney E A, et al.
Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review.
Gastroenterology.
1996;
110
1244-1252
-
90
Vanderhulst R M, Rauws E J, Koycu B, et al.
Prevention of ulcer recurrence after eradication of Helicobacter pylori - A prospective long-term follow-up study.
Gastroenterology.
1997;
113
1082-1086
-
91
Labenz J, Blum A L, Bayerdorffer E, et al.
Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis.
Gastroenterology.
1997;
112
1442-1447
-
92
Forbes G M, Glaser M E, Cullen D J, et al.
Duodenal ulcer treated with Helicobacter pylori eradication: seven-year follow-up.
Lancet.
1994;
343
258-260
-
93
Goulston K J, Dent O F, Logan J, et al.
Use of H2-receptor antagonists in patients with dyspepsia and heartburn: a cost comparison.
Med J Aust.
1991;
155
20-26
-
94
Goodson J D, Lehmann J W, Richter J M, et al.
Is upper gastrointestinal radiography necessary in the initial management of uncomplicated dyspepsia? A randomized controlled trial comparing empiric antacid therapy plus patient reassurance with traditional care.
J Gen Intern Med.
1989;
4
367-374
-
95
Bytzer P, Hansen J M, Schaffalitzky de Muckadell O B.
Empirical H2-blocker therapy or prompt endoscopy in management of dyspepsia.
Lancet.
1994;
343
811-816
-
96
Bloom B S.
Cross-national changes in the effects of peptic ulcer disease.
Ann Intern Med.
1991;
114
558-562
-
97
Westbrook J I, Rushworth R L.
The epidemiology of peptic ulcer mortality 1953 - 1989: a birth cohort analysis.
Intern J Epidemiol.
1993;
22
1085-1092
-
98
La Vecchia C, Lucchini F, Negri E, et al.
The impact of therapeutic improvements in reducing peptic ulcer mortality in Europe.
Intern J Epidemiol.
1993;
22
96-106
-
99
Msika S, Tazi M A, Benhamiche A M, et al.
Population-based study of diagnosis, treatment and prognosis of gastric cancer.
Brit J Surg.
1997;
84
1474-1478
-
100
Kahn K.
Endoscopy in the evaluation of dyspepsia. Health and Public Policy Committee, American College of Physicians.
Ann Intern med.
1985;
102
266-269
-
101
American Society for Gastrointestinal Endoscopy.
The role of endoscopy in the management of the patient with peptic ulcer disease. Guidelines for clinical application.
Gastrointest Endosc.
1988;
34
4-25S
-
102
Bytzer P.
Diagnosing dyspepsia: any controversies left?.
Gastroenterology.
1996;
110
302-306
-
103
Tham T C.
Application of serological screening for Helicobacter pylori in reducing endoscopy workload.
Gastroenterology.
1993;
104
A26
-
104
Lassen A T.
H. Pylori “test and treat” or prompt endoscopy for dyspeptic patients in primary care. A randomized controlled trial of two management strategies: one year follow-up. (Abstract).
Gastroenterology.
1998;
114
A196-196
-
105
Jones R H.
A Helicobacter test and treat strategy: costs and outcomes in a randomized controlled trial in primary care. (Abstract).
Gastroenterology.
1998;
114
A20-20
-
106
Ofman J J, Etchason J, Fullerton S, et al.
Management strategies for Helicobacter pylori-seropositive patients with dyspepsia - clinical and economic consequences.
Ann Intern Med.
1997;
126
280-291
-
107
Briggs A H, Sculpher M J, Logan R P, et al.
Cost effectiveness of screening for and eradication of Helicobacter pylori in management of dyspeptic patients under 45 years of age.
Br Med J.
1996;
312
1321-1325
-
108
Fullerton F.
Empiric antibiotic therapy versus early endoscopy in dyspeptic patients with positive serologic test for Helicobacter pylori: a decision analysis. (Abstract).
Gastroenterology.
1995;
108
A15
-
109
Silverstein F E, Graham D Y, Senior J R, et al.
Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial.
Ann Intern Med.
1995;
123
241-249
-
110
Fendrick A M, Chernew M E, Hirth R A, Bloom B S.
Immediate endoscopy or initial Helicobacter pylori serological testing for suspected peptic ulcer disease: estimating cost-effectiveness using decision analysis.
Yale Journal of Biology & Medicine.
1996;
69
187-195
-
111
Eckardt V F, Giessler W, Kanzler G, Bernhard G.
Does endoscopic follow-up improve the outcome of patients with benign gastric ulcers and gastric cancer?.
Cancer.
1992;
69
301-305
-
112
Farinati F, Cardin F, Di Mario F, et al.
Early and advanced gastric cancer during follow-up of apparently benign gastric ulcer: significance of the presence of epithelial dysplasia.
J Surg Oncol.
1987;
36
263-267
-
113
Tragardh B, Haglund U.
Endoscopic diagnosis of gastric ulcer. Evaluation of the benefits of endoscopic follow-up observation for malignancy.
Acta Chir Scand.
1985;
15
37-41
-
114
Bytzer P.
Endoscopic follow-up study of gastric ulcer to detect malignancy: is it worthwhile?.
Scandinavian Journal of Gastroenterology.
1991;
26
1193-1199
-
115
Pruitt R E, Truss C D.
Endoscopy, gastric ulcer, and gastric cancer. Follow-up endoscopy for all gastric ulcers?.
Dig Dis Sci.
1993;
38
284-288
-
116
Hansson L E, Nyren O, Hsing A W, et al.
The risk of stomach cancer in patients with gastric or duodenal ulcer disease.
N Engl J Med.
1996;
335
242-249
-
117
Talley N J, Evans J M, Fleming K C, et al.
Nonsteroidal antiinflammatory drugs and dyspepsia in the elderly.
Dig Dis Sci.
1995;
40
1345-1350
-
118
Graham D Y.
Treatment of peptic ulcers caused by Helicobacter pylori (editorial; comment).
N Engl J Med.
1993;
328
349-350
-
119
Gabriel S E, Jaakkimainen L, Bombardier C.
Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis.
Ann Intern Med.
1991;
115
787-796
-
120
Larkai E N, Smith J L, Lidsky M D, Graham D Y.
Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use.
Am J Gastroenterol.
1987;
82
1153-1158
-
121
Battistini B, Botting R, Bakhle Y S.
COX-1 and COX-2: toward the development of more selective NSAIDs.
Drug News and Perspectives (Barcelona).
1994;
7
501-512
-
122
Distel M, Mueller C, Bluhmki E, Fries J.
Safety of meloxicam: a global analysis of clinical trials.
Brit J Rheumatol.
1996;
35
68-77
-
123
Roth S H, Bennett R, Caldron P, et al.
A longterm endoscopic evaluation of patients with arthritis treated with nabumetone vs naproxen.
J Rheumatol.
1994;
21
1118-1123
-
124
Porro G B, Montrone F, Petrillo M, et al.
Gastroduodenal tolerability of nabumetone versus naproxen in the treatment of rheumatic patients.
Am J Gastroenterol.
1995;
90
1485-1488
-
125
Allison M C, Howatson A G, Torrance C J, et al.
Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs (see comments).
N Engl J Med.
1992;
327
749-754
-
126
Graham D Y, Lidsky M D, Cox A M, et al.
Long-term nonsteroidal antiinflammatory drug use and Helicobacter pylori infection.
Gastroenterology.
1991;
100
653-657
-
127
Loeb D S, Talley N J, Ahlquist D A, et al.
Long-term nonsteroidal anti-inflammatory drug use and gastroduodenal injury: the role of Helicobacter pylori.
Gastroenterology.
1992;
102
1899-1905
-
128
Chan F K, Sung J J, Chung S C, et al.
Randomized trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers.
Lancet.
1997;
350
975-979
-
129
Lai K C.
Eradication of Helicobacter pylori did not accelerate the healing of gastric and duodenal ulcers/erosions in patients on long-term continuous nonsteroidal anti-inflammatory drugs. (Abstract).
Gastroenterology.
1998;
114
A192
-
130
Lai K C.
Can eradication of Helicobacter Pylori prevent future development of peptic ulcers in patients receiving long-term continuous nonsteroidal anti-inflammatory drugs. (Abstract).
Gastroenterology.
1998;
114
A192
-
131
Hawkey C J, Tullassay Z.
Failure of Helicobacter Pylori eradication to influence site-specific relapse in high risk NSAID users: results of a large six month double blind randomized controlled clinical trial. (Abstract).
Gastroenterology.
1998;
114
A145
-
132
Koch M, Dezi A, Ferrario F, Capurso L.
Prevention of nonsteroidal anti-inflammatory drug-induced gastrointestinal mucosal injury - a meta-analysis of randomized controlled clincal trials. (Abstract).
Arch Intern Med.
1996;
156
2321-2332
-
133
Taha A S, Hudson N, Hawkey C J, et al.
Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs.
N Engl J Med.
1996;
334
1435-1439
-
134
Agrawal N M, Van Kerckhove H E, Erhardt L J, Geis G S.
Misoprostol coadministered with diclofenac for prevention of gstroduodenal ulcers. a one-year study.
Dig Dis Sci.
1995;
40
1125-1131
-
135
Hudson N, Taha A S, Russell R I, et al.
Famotidine for healing and maintenance in nonsteroidal anti-inflammatory drug-associated gastroduodenal ulceration (see comments).
Gastroenterology.
1997;
112
1817-1822
-
136
Ekstrom P, Carling L, Wetterhus S, et al.
Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. A Nordic multicentre study.
Scan J Gastroenterol.
1996;
31
753-758
-
137
Yeomans N D, Tulassay Z, Juhasz L, et al.
A Comparison of Omeprazole with Ranitidine for Ulcers Associated with Nonsteroidal Antiinflammatory Drugs.
N Engl J Med.
1998;
338
719-726
-
138
Hawkey C J, Karrasch J A, Szczepanski L, et al.
Omeprazole Compared with Misoprostol for Ulcers Associated with Nonsteroidal Antiinflammatory Drugs.
N Engl J Med.
1998;
338
727-734
-
139
Martin L F.
Stress ulcers are common after aortic surgery. Endoscopy evaluation of prophylactic therapy.
Am Surg.
1994;
60
169-174
-
140
Cook D J, Reeve B K, Guyatt G H, et al.
Stress ulcer prophylaxis in critically ill patients. Resolving discordant meta-analyses.
J Am Med Ass.
1996;
275
308-314
-
141
Zandstra D F, Stoutenbeek C P.
The virtual absence of stress-ulceration related bleeding in ICU patients receiving prolonged mechanical ventilation without any prophylaxis. A prospective cohort study (see comments).
Intens Care Med.
1994;
20
335-340
-
142
Cook D J, Fuller H D, Guyatt G H, et al.
Risk factors for gastrointestinal bleeding in critically ill patients. Canadian Critical Care Trials Group.
N Engl J Med.
1994;
330
377-381
-
143
Levy M J, Seelig C B, Robinson N J, Ranney J E.
Comparison of omeprazole and ranitidine for stress ulcer prophylaxis.
Dig Dis Sci.
1997;
42
1255-1259
-
144
Schepp W, Schusdziarra V, Classen M.
(Stress ulcer prophylaxis 1995. Balancing between gastrointestinal bleeding and nosocomial pneumonia.)
Dtsch Med Wochenstr.
1995;
120
573-579
-
145
Marrone G C, Silen W.
Pathogenesis, diagnosis and traetment of acute gastric mucosal lesions.
Clin Gastroenterol.
1984;
13
635-650
-
146
De Bosset V, Gonvers J J, Froehlich F, et al.
Appropriateness of gastroscopy: Bleeding and dysphagia.
Endoscopy.
1999;
31
615-622
-
147
Hudson N.
Excess long-term mortality in patients with ulcer complications.
Lancet.
1997;
349
968-969
-
148
Svanes C, Lie R T, Lie S A, et al.
Survival after peptic ulcer perforation: a time trend analysis.
J Clin Epidemiol.
1996;
49
1363-1371
-
149
Svanes C, Salvesen H, Stangeland L, et al.
Perforated peptic ulcer over 56 years. Time trends in patients and disease characteristics.
Gut.
1993;
3
1666-1671
-
150 International Agency for Research on Cancer. Atlas of cancer mortality in the European Economic Community. In: Smans M, Muir CS, Boyle P (eds). Lyon, France; IARC, 1992
-
151 International Agency for Research on Cancer. Atlas of cancer mortality in Central Europe. In: Zatonski W, Smans M, Tyczynski J, et al. (eds). Lyon, France; IARC, 1996
-
152
Fuchs C S, Mayer R J.
Gastric carcinoma.
N Engl J Med.
1995;
333
32-41
-
153
Gasbarrini G, Genta R M, Anti M, et al.
Update on Helicobacter pylori research. Malignancies.
Eur J Gastroenterol Hepatol.
1997;
9
621-623
-
154
Forman D, Newell D G, Fullerton F, et al.
Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation.
Brit Med J.
1991;
302
1302-1305
-
155
Parsonnet J, Friedman G D, Vandersteen D P, et al.
Helicobacter pylori infection and the risk of gastric carcinoma.
N Engl J Med.
1991;
325
1127-1131
-
156
Nomura A, Stemmermann G N, Chyou P H, et al.
Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii.
N Engl J Med.
1991;
325
1132-1136
-
157
Blaser M J, Chyou P H, Nomura A.
Age at establishment of Helicobacter pylori infection and gastric carcinoma, gastric ulcer, and duodenal ulcer risk.
Cancer Res.
1995;
55
562-565
-
158
Matley P J, Dent D M, Madden M V, et al.
Gastric carcinoma in young adults.
Ann Surg.
1988;
208
593-596
-
159
Moreno-Otero R, Rodriguez S, Carbo J, et al.
Acute upper gastrointestinal bleeding as primary symptom of gastric carcinoma.
J Surg Oncol.
1987;
36
130-133
-
160
Schlemper R J, Itabashi M, Kato Y, et al.
Differences in diagnostic criteria for gastric carcinoma between Japanese and Western pathologists.
Lancet.
1997;
349
1725-1729
-
161
Farinati F, Rugge M, Di Mario F, et al.
Early and advanced gastric cancer in the follow-up of moderate and severe gastric dysplasia patients. a prospective study. i. g. g. e. d.-interdisciplinary group on gastric epithelial dysplasia.
Endoscopy.
1993;
25
261-264
-
162
Hallissey M T, Allum W H, Jewkes A J, et al.
Early detection of gastric cancer.
Brit Med J.
1990;
301
513-515
-
163
Caprilli R, Andreoli A, Capurso L, et al.
Oral mesalazine (5-aminosalicylic acid; Asacol) for the prevention of post-operative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC).
Alimentary Pharmacology & Therapeutics.
1994;
8
35-43
-
164
Iwao T, Toyonaga A, Ikegami M, et al.
McCormack's endoscopic signs for diagnosing portal hypertension: comparison with gastroesophageal varices.
Gastrointest Endosc.
1994;
40
470-473
-
165
Ziegler K, Sanft C, Zimmer T, et al.
Comparison of computed tomography, endosonography, and intraoperative assessment in tn staging of gastric carcinoma.
Gut.
1993;
34
604-610
-
166
Dittler H J, Siewert J R.
Role of endoscopic ultrasonography in gastric carcinoma.
Endoscopy.
1993;
25
162-166
-
167
Grimm H, Binmoeller K F, Hamper K, et al.
Endosonography for preoperative locoregional staging of esophageal and gastric cancer.
Endoscopy.
1993;
25
224-230
1 The European Panel on Appropriateness of Gastrointestinal Endoscopy (EPAGE, Lausanne, Switzerland)
Florian FroehlichMD PD
Policlinique Médicale Universitaire
Rue César-Roux 19
CH-1005 Lausanne
Switzerland
Phone: +41-32-466 29 55
Email: florian.froehlich@bluewin.ch
